Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

NCT01852110 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

240

Enrollment

INDUSTRY

Sponsor class

Stopped Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.

Conditions

Alzheimer's Disease

Interventions

DRUG: MK-7622
DRUG: Placebo
DRUG: AChEI

Sponsor

Merck Sharp & Dohme LLC